Jul 27, 2026 · 6 min
Non-tech stocks surge and plunge as energy gains and biotech craters
Baker Hughes Gains, Capricor Plunges, Meatpackers Jump
Understanding market dynamics outside of tech is essential for identifying broader economic trends in energy, healthcare regulation, and global trade.
- 1Baker Hughes shares climbed over five percent following strong second-quarter earnings and upgraded full-year guidance.
- 2Capricor Therapeutics plummeted about 65 percent after the FDA raised concerns over its clinical trial data.
- 3Tyson Foods and meatpackers rallied following the USDA decision to resume cattle imports from Mexico.
Don't miss
Capricor Therapeutics suffers a devastating 65 percent stock collapse following critical FDA feedback on its clinical trial data.
The brief
While tech dominates the headlines, major market shifts are happening elsewhere. Bloomberg equities reporter Avalon Purnell joins hosts Carol Massar and Tim Stenovec to break down the non-tech stock movements driving the market.
Energy giant Baker Hughes jumped over five percent after posting strong second-quarter profits and raising its full-year guidance, signaling robust demand and operational strength in the global energy sector.
In contrast, biotech firm Capricor Therapeutics saw its stock plunge roughly 65 percent. The massive sell-off was triggered by regulatory hurdles, specifically FDA concerns regarding the company's clinical trial data.
Meanwhile, meat producers like Tyson Foods experienced a sharp rise. The gains came after the USDA confirmed that Mexican cattle imports can officially resume, resolving a major supply chain bottleneck for the industry.
What was said on this episode
3 statements · 2 positive · 1 mixed
Citi views resumed Mexican cattle imports as a positive catalyst for the meat sector.
“Citi also writing that they see this as a very positive catalyst for the sector as a whole.”
Listen at 3:33
JBS may benefit most from resumed Mexican cattle imports because of its leading U.S. beef exposure.
“though they do believe that JBS may actually be the biggest one to actually benefit from this, given the fact that it's been a tough year for meats and they have the leading exposure in U.S. beef.”
Listen at 3:42
Lower cattle costs may not necessarily reduce consumer meat prices.
“It kind of depends. I mean, that's not the only place where we get meat, but definitely something we'll keep an eye on.”
Listen at 4:13
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Capricor Therapeutics, Inc.
Food and Drug Administration
Tyson FoodsBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.